$SI

Gilde Healthcare Holding B.V. sold $1.1M of SI (indirect holdings)

Gilde Healthcare Holding B.V. sold 48,279 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $23.10 ($22.73–$23.36, $1.12M total) across 2 trades over 2026-07-30 to 2026-07-31.

Original reporting
SEC EDGAR · Gilde Healthcare Holding B.V.
Published Aug 3, 2026, 9:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SI
Neutral
low confidence
Mentioned
$SI
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SINeutralLow
01

Why it matters

The disclosed event is a $1.12M open-market sale by a 10% owner via indirect holdings, with no 10b5-1 plan cited.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The article does not state the owner’s remaining intent, whether other related entities sold, or any offsetting purchases.

Relevance 6/10Novelty 5/10Timing: filed Aug 3, 2026 after-hours; reflects sales executed July 30-31

Background

The article is an SEC Form 4 insider transaction disclosure for Shoulder Innovations, Inc. (SI).

Company-level read

Ticker impact

$SINeutralLow confidence
Context

Shoulder Innovations, Inc. (SI) is the Form 4 issuer, and Gilde Healthcare Holding B.V. sold $1.12M of SI shares via an open-market sale.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on filings show sustained selling.

Evidence & confidence

The filing is a routine Form 4 transaction with no 10b5-1 plan and no accompanying company-specific operational or financial update.

Market effects

No sector read-through; this is company-specific insider selling disclosure.

None indicated.

None indicated.

Counterpoint

A sale by a 10% owner can be liquidity-driven (taxes, diversification) and may not signal reduced confidence.

Key entities

  • Shoulder Innovations, Inc.

    Company whose shares were sold in the reported Form 4 transaction.

  • Gilde Healthcare Holding B.V.

    Reporter of the indirect holdings sale as a 10% owner.

Related articles

$SIMed

Siemens to acquire EDA software firm Precision Innovations

Siemens said it signed an agreement to acquire privately held US EDA software firm Precision Innovations. Siemens said the deal will add AI-powered chip planning and early design exploration using the OpenROAD framework to help semiconductor teams optimize power, performance and area, reduce iterations, and speed SoC feasibility analysis and time to market.

$SIMedAI 8/10

SHOULDER INNOVATIONS, INC. (SI): Results of Operations and Financial Condition

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-991earningsreleaseq22026.htm EX-99.1 Document Exhibit 99.1 Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook Generates First Half 2026 Revenue Growth of 60% Grand Rapids, MI – August 6, 2026 – Shoulder Innovations, Inc. (

$SIMed

Siemens to acquire chip design firm Precision Innovations

Siemens said it agreed to acquire privately held Precision Innovations Inc., an electronic design automation firm. Siemens will add Precision’s AI-powered chip planning tools to its EDA portfolio to help semiconductor teams evaluate design tradeoffs earlier in system-on-a-chip development, aiming to improve power, performance and area outcomes and speed time to production.

$QTTBMedAI 8/10

Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus

Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.